Genelux Corporation (NASDAQ:GNLX) Financings
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$5.1M raised Use of proceeds: Together with existing cash, expected to fund operations into the first quarter of 2027 | Nov 16, 2026 |
| Public offering of common stock Announced: about US$20M · US$3 a share · Lucid Capital Markets Dealers: Lucid Capital Markets (lead) Use of proceeds: General corporate purposes, possibly including research and development, clinical trial expenses, capital expenditures and working capital | Jan 8, 2026 |
| Public offering of common stock Closed: US$10.5M raised · US$3.5 a share · Titan Partners Group, a division of American Capital Partners Dealers: Titan Partners Group, a division of American Capital Partners (lead) Use of proceeds: Working capital and general corporate purposes, including continued clinical development of Olvi-Vec | Mar 28, 2025 |